Evidence map›Paper›PMID 39543334›Full record

ArticleThe Journal of antibiotics2025

Structure-activity relationship studies of ME1111, a novel antifungal agent for topical treatment of onychomycosis.

Naomi Takei-Masuda, Maiko Iida, Makoto Ohyama, Kaori Kaneda, Kenji Ueda, Yuji Tabata

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Naomi Takei-MasudaMeiji Seika Pharma Co. Ltd, Chuo-ku, Tokyo, Japan. naomi.takei@meiji.com.
Maiko IidaMeiji Seika Pharma Co. Ltd, Chuo-ku, Tokyo, Japan.
Makoto OhyamaMeiji Seika Pharma Co. Ltd, Chuo-ku, Tokyo, Japan.
Kaori KanedaMeiji Seika Pharma Co. Ltd, Chuo-ku, Tokyo, Japan.
Kenji UedaCollege of Bioresource Sciences, Nihon University, Kanagawa, Japan.
Yuji TabataMeiji Seika Pharma Co. Ltd, Chuo-ku, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Onychomycosis is a prevalent disease in many areas of the world, affecting approximately 5.5% of the global population. Among several subtypes of onychomycosis, distal-lateral-subungual onychomycosis is the most common, and topical onychomycosis agents effective against this pathogenesis require properties such as high nail penetration and low affinity for keratin, the main component of the nail. To develop novel and highly effective antifungal agents with such properties, we first established an efficient ex vivo evaluation method using bovine hoof slices and human nails, and then used this method to screen an in-house compound library. Using this strategy, we identified 1, a structure with a phenyl-pyrazole skeleton. In subsequent analyses, we investigated the structure-activity relationship of 1, permitting the identification of 28 (Development Code ME1111).

Indexed as

Administration, TopicalAntifungal AgentsOnychomycosisAnimalsCattleHoof and ClawHumansMicrobial Sensitivity TestsNailsPyrazolesStructure-Activity RelationshipAntifungal AgentsPyrazoles

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.